Is Nexgel Inc (NXGL) Stock a Good Investment?
Learn more about Nexgel Inc's (NXGL) stock grades for Value, Growth and Estimate Revisions and determine whether this Pharmaceuticals stock meets your investment needs.Issac Deleon
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Commentary & Analysis
Financial Summary
| Share Statistics | NXGL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.3 | $416.1 | 2% |
|
| Shares Out (Mil) | 9.0 | 41.6 | 19% |
|
| Institutional Ownership | 31.0% | 83.1% | 13% |
|
| Float (Mil) | 7.7 | 35.6 | 16% |
|
| Beta | 0.77 | 0.88 | 46% |
|
| Avg Daily Volume (000s) | 2,773 | 333 | 88% |
|
| Price Change (52-week) |
(85.4%) | 65.0% | 5% |
|
| Growth | NXGL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 74.7% | 11.8% | 98% |
|
| Net Income (5yr) | (5.5%) | (5.9%) | 33% |
|
| EPS (5yr) | 17.6% | 10.2% | 63 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 0.0% | (15.6%) | 64% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.240) | ($0.940) | ($0.220) | |
| Month Ago EPS | ($0.040) | ($0.120) | $0.400 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.040) | ($0.120) | $0.400 | |
| Year/Year Chg | (40.4%) | 146.1% | (86.9%) | |
| Financials | NXGL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $12 | $119 | 10% |
|
| Net Income (TTM) (Mil) | ($6) | ($9) | 32% |
|
| EPS (TTM) | ($0.748) | ($0.400) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($3) | 27% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $1 | 46% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $22 | 26% |
|
| Enterprise Value (Q1) (Mil) | $11 | $371 | 8% |
|
| Valuation | NXGL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.67 | 3.00 | 11% |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.6 | na |
|
| Ratios | NXGL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 35.1% | 58.5% | 42% |
|
| Net Margin | (51.3%) | (6.9%) | 12% |
|
| ROA | (34.2%) | (13.4%) | 16% |
|
| ROE | (128.6%) | (13.6%) | 7% |
|
| Liabilities to Assets | 79.3% | 46.1% | 74% |
|
| F-Score | 1 | 4 | 1% |
|
NEXGEL, Inc. did not pass any screens on 9/2/2026.
